Ann: FELIX product development and commercialisation update, page-6

 A price rise is ideal, and the stagnant nature of the stock at the moment I wouldn't say it has hit a doldrums. I think of it as market stability. The market has quite strongly priced the company with its current situation at about 2.8 - 3.2 cents. No one wants to buy, but no one wants to sell either. Its not as sexy as a fast rise to 10 cents, but this demonstrates that there are firm believers in the company, but at the same time, equal amount of speculation.

Personally, I sense confidence in the management team. If I wasn't confident, I wouldn't be giving my product to prominent experts within the market I'm trying to penetration (excuse my pun). As important as having a good product is the management of business development. Working alongside Monash, the leading IVF clinics in Australia, to support their commercialization is very positive and well-planned out. I'm assuming Monash will be providing MEM with important challenges and expectations of male IVF to ensure the product is fast-tracked for successful delivery.

I've said it before, the management team has been very thorough during the whole process of product release, and I'm definitely feeling confident with the company.